

Cambridge University Press

978-0-521-85652-2 - Philosophy of Psychopharmacology: Smart Pills, Happy Pills, and pep Pills

Dan J. Stein

Index

[More information](#)

Index

- adverse effects of psychotropics 5
- ageing, evolutionary perspective 92–3, 96
- alcoholism 96
- analytic philosophy 19–20
- anthropology
 - categorization models 30
 - data on emotion 56
 - data on the self 63–4
- anti-psychiatry movement 6, 62, 66
- Aristotle 40
- artificial intelligence
 - categorization models 29–30
 - view of the self 63
- attention-deficit/hyperactivity disorder (ADHD) 8, 46, 96
- avoidant personality disorder (APD) 52
- avoidant personality traits 57–9
- Ayer, Alfred 20–1

- barbiturates 15
- basic psychopharmacology 1
- behavioural inhibition 57–9
- behaviourism 19–20, 23, 51–2
- benzodiazepines 15
- bioethical principlism 103–4
- bioethics
 - classical approach 99
 - critical position 99
 - realist, naturalist and embedded position 99–100
 - use of pharmacotherapy for enhancement 116–30
 - see also* ethics
- biopsychosocial model of psychiatric disorder 41
- bipolar disorder 8

- brain-behaviour phenomena, explanatory questions viii
- brain-mind
 - classical approach ix
 - critical approach ix
 - data from cognitive-affective science 74–6
 - definition of the term x
 - embodiment of emotion 54–9
 - embodiment of the self 62–5
 - evolutionary psychology approach 86
 - functionalist view 72–3
 - implications of placebo and nocebo responses 81–2
 - integrative approach ix
 - mapping 74–6
 - see also* embodied brain-mind

- cannabis 87
- care ethics 104
- Carnap, Rudolf 20–1
- categorization
 - classical approach 19
 - comparison of physical and social worlds 39–40
 - critical approach 22
- categorization models
 - anthropology and neuroscience 30
 - artificial intelligence 29–30
 - cognitive psychology 28–9
 - connectionist models 29–30, 31
 - developmental cognitive-affective science 31
 - evolutionary theory 30–1
 - graded structure of categories 28–9
 - linguistics 29

Cambridge University Press

978-0-521-85652-2 - Philosophy of Psychopharmacology: Smart Pills, Happy Pills, and pep Pills

Dan J. Stein

Index

[More information](#)**202 Index**

- categorization models (*cont.*)
 - naturalist approach 27–34
 - neuroscience and anthropology 30
 - use of prototypes 28–9, 30
- category of disorders
 - cognitive-affective mappings 34–8
 - impact of novel medical interventions 38–9
 - metaphors of disorder 34–8
 - structure 34–41
 - use of prototypes 40, 41
- character, definition of 12
- chlorpromazine 4
- classical approach ix, 19–22
 - categorization 19
 - classification of emotions 52
 - definition of medical and psychiatric disorder 20, 21–2
 - definition of psychiatric disorder 25–6
 - definition of the self 59–61
 - emotion 51–2
 - influences in psychology and psychiatry 19–20
 - organic model of psychiatric disorder 25–6
 - philosophy of mind 21
 - physical and psychological phenomena 20
 - science and language 19–22
 - use of algorithms 19–22
- clinical psychopharmacology 1
- clomipramine 7–8, 76, 84–5
- cocaine 15
- cognition, link with emotion 54–5, 59
- cognitive-affective, definition of the term ix–x
- cognitive-affective mappings of categories 34–8
- cognitive-affective scientific data
 - brain-mind 74–6
 - choice of treatment 113–14
 - distinctions between psychotropics 47–8
- emotion 54–9
- enhancement vs treatment debate 121–9
- ethics of treatment of psychiatric disorders 104–6
- evolutionary psychology 86–97
- mechanisms of psychotropics 74–6
- nocebo response 83–4
- placebo response 80–1, 83–4
- social anxiety 57–9
- the self 62–5
- the unconscious 83–4
- cognitive-enhancing agents 44–50
- cognitive psychology
 - categorization models 28–9
 - data on emotion 54–5
 - link between cognition and emotion 54–5
 - view of the self 63
- cognitive therapy, ethical questions 101, 102
- cognitivism 51–2, 77–8
- computational modelling, emotion 55
- conceptual questions related to psychotropics
 - boundaries with legal and illegal drugs 12
 - categories used to define disorders 12
 - definition of a pharmaceutical 12
 - definition of a psychotropic 12
 - definition of character and the self 12
 - definition of medical or psychiatric disorder 12
 - distinction between mechanisms of action 12
 - distinction between therapy and enhancement 12
 - effects of psychotropics 11–12
 - nature of emotion 51–9
 - nature of psychotropics 44–50
 - nature of the self 59–68

Cambridge University Press

978-0-521-85652-2 - Philosophy of Psychopharmacology: Smart Pills, Happy Pills, and pep Pills

Dan J. Stein

Index

[More information](#)

- connectionist models 29–30, 31
- continental philosophy 32–3, 61
- cosmetic psychopharmacology vii–ix, 14–15, 92–3, 96, 117–18
- critical approach ix, 22–5
 - categorization 22
 - clinical models of psychiatric disorder 26–7
 - common themes 22
 - definition of medical disorder 24–5
 - definition of psychiatric disorder 26–7
 - definition of the self 61–2
 - emotion 52–4
 - influences in philosophy 22
 - influences in psychology and psychiatry 22
 - language 23
 - philosophy of mind 23–4
 - philosophy of science 22–3
 - psychological phenomena 23–4
- depression
 - ethics of treatment 100–6
 - ethics of use of pharmacotherapy 109–10, 114
 - placebo response 80–1
- depressive realism viii, 14, 101–2
- Descartes, René 51–2, 59–60
- desipramine 7–8
- developmental cognitive-affective science
 - categorization models 31
 - data on the self 64–5
 - view of emotion 56
- Diagnostic and Statistical Manual 4th edition (DSM-IV) 52, 58
- disorder
 - evolutionary explanations 87–97
 - integrative approach 88–97
 - questions about definition 12
 - see also* medical disorder; psychiatric disorder
- dopamine blockers, discovery of 4
- dysfunction concept, evolutionary explanations 87–97
- embodied brain-mind
 - categorization models 27–34
 - ideas from philosophy 31–3
 - mediation of psychiatric intervention 77–8
 - mediation of psychiatric pathology 77–8
 - use of prototypes 28–9, 30
 - see also* brain-mind
- embodiment of emotion 54–9
- embodiment of the self 62–5
- emotion
 - anthropological data 56
 - appropriateness of 56–7
 - classical approach 51–2
 - classification 52
 - computational modelling 55
 - conceptual work in philosophy 56–7
 - contrast with reason 51–2
 - critical view 52–4
 - cross-cultural data 56
 - data from cognitive-affective science 54–9
 - data from cognitive psychology 54–5
 - data from developmental psychology 56
 - embodiment in the brain-mind 54–9
 - evolutionary scientific data 56
 - integrative approach 54–9
 - linguistic data 56
 - link with cognition 54–9
 - medicalization of emotional experience 53–4
 - nature of 51–9
 - neuroscientific data 55–6
 - see also* social anxiety (disorder)
- enhancement
 - cosmetic psychopharmacology 117–18
 - distinction from therapy 12
 - distinction from treatment 44–50
 - ethics of use of pharmacotherapy 116–30
 - moral questions 14–15
 - use of psychotropics 14–15

Cambridge University Press

978-0-521-85652-2 - Philosophy of Psychopharmacology: Smart Pills, Happy Pills, and pep Pills

Dan J. Stein

Index

[More information](#)**204 Index**

- enhancement vs treatment
 - case examples 117
 - classical view 118–19
 - critical perspective 119–20
 - data from cognitive-affective science 121–9
 - difficulty of predicting psychotropic response 127–9
 - drive for self-improvement 120
 - expectations and motivations 124–7
 - integrative perspective 119–29
 - limitations of current
 - psychopharmacology 127–9
 - loss of authenticity 120
 - neuroethics 129–30
 - ‘paradox of health’ 124
 - preventive interventions 122
 - SSRIs 128
 - use of embodied metaphors in moral reasoning 121–2
 - use of genetic variant profiling 127
- entheogens 2–3, 45
- ethical questions
 - classical approach 99
 - critical position 99
 - medical decision-making 104–6
 - placebo-controlled trials 81
 - realist, naturalist and embedded position 99–100
 - social anxiety disorder treatment 106–8
 - treatment of impulsivity 108–9
 - treatment of psychiatric disorders 100–9
 - use of pharmacotherapy 109–16
 - use of pharmacotherapy for enhancement 116–30
- evolutionary approaches to medicine
 - classical perspective 85
 - critical perspective 85–6
- evolutionary psychology 86–97
 - and brain-mind mechanisms 86
 - constructs of function and dysfunction 87–97
 - cross-species effects of psychotropics 86–7
 - explanation of pharmacotherapy effects 86–7
 - explanation of psychiatric disorder 87–97
 - gene-environment interactions 93–4
 - genetic changes 93–4
 - integrative approach 88–97
 - reliance on behavioural modules 93
 - spandrels 94–5
- evolutionary psychopharmacology 84–97
- evolutionary science
 - ageing 92–3, 96
 - data on emotion 56
 - data on the self 64–5
 - distinctions between psychotropics 47–8
 - evolutionary theory, categorization models 30–1
 - psychotropic actions 13–14
- exemplars *see* prototypes
- explanatory questions about
 - psychotropics
 - brain-behaviour phenomena viii
 - constructs of function and dysfunction 87–97
 - evolutionary perspective 13–14
 - evolutionary psychopharmacology 84–97
 - how psychotherapy works 70–8
 - how psychotropics work 13–14, 70–8
 - nocebo effects 13, 78–84
 - placebo effects 13, 78–84
 - psychotropic drug mechanisms viii
 - understanding how treatment works 13
- fluoxetine 4, 14–15, 87
- Frege, Gottlob 20
- Freud, Sigmund 61, 62, 67–8, 74, 82–3, 85
- function concept, evolutionary
 - explanations 87–97
- functionalist view
 - concept of the mind 72–3
 - effects of pharmacotherapy 77
 - effects of psychotherapy 77

Cambridge University Press

978-0-521-85652-2 - Philosophy of Psychopharmacology: Smart Pills, Happy Pills, and pep Pills

Dan J. Stein

Index

[More information](#)

- gene-environment interactions 93–4
- gene therapy 15
- genetic changes, evolutionary perspective 93–4
- genetic variant profiling, use for treatment and enhancement 127
- happy pills 45
- Hegel, Georg Wilhelm Friedrich 99
- herbal agents 48, 49
- Herder, Johann Gottfried ix, 22–3
- Hippocrates 40
- Hume, David 20, 61, 63, 65–6, 104
- impulsive behaviours, ethics of decision to treat 108–9
- individual, concept of 60–1 *see also* self 61–2
- inositol 44, 48–9
- integrative approach
 - brain-mind ix
 - classical and critical foundations ix
 - emotion 54–9
 - social anxiety (disorder) 57–9
- interpersonal psychoanalysis 22
- James, William 56, 61
- Kant, Immanuel 20, 32, 51–2, 59–60, 99, 103
- Lakoff, George 29
- linguistics
 - categorization models 29
 - data on emotion 56
 - data on the self 63–4
- lived-body concept 32–3
- Locke, John 31–2, 60–1
- logical positivism 19–21
- medical decision-making, ethics of 104–6
- medical disorder
 - as dysfunction 21–2
 - as social construct 24–5
- classical definition 20, 21–2
- conceptual questions viii
- critical approach to definition 24–5 *see also* disorder; psychiatric disorder
- medical technologies, concerns about 112–13
- medicalization of emotional experience 53–4, 103–4, 112–13
- Merleau-Ponty, Maurice 65–6, 67–8
- metaphors of disorder 34–8
- methylphenidate 46
- military, use of psychotropics for
 - performance enhancement 5, 8
- Mill, John Stuart 20, 103
- mind *see* brain-mind; embodied
 - brain-mind; philosophy of mind
- monoamine oxidase inhibitors, discovery of 4
- moral questions about use of
 - psychotropics viii, 14–15
 - appropriate symptoms for treatment 14
- cosmetic psychopharmacology 14–15
- pharmacotherapeutic intervention 109–16
- treatment of psychiatric disorders 100–9
- use for enhancement/self-improvement 14–15, 116–30
- naturalist approach
 - categorization of psychiatric disorders 27–34
 - philosophy of psychopharmacology 131–40
- neuroethics 129–30
- neurogenetics 64
- neuromodulatory effects of psychotropics 4–5
- neuroscience
 - categorization models 30
 - data on emotion 55–6
 - data on the self 64
 - distinctions between psychotropics 47

Cambridge University Press

978-0-521-85652-2 - Philosophy of Psychopharmacology: Smart Pills, Happy Pills, and pep Pills

Dan J. Stein

Index

[More information](#)**206 Index**

- neutraceuticals 12, 48–9
- nocebo response viii, 13, 80–1
 - and symbolic grounding 81–2
 - cognitive-affective science perspective 83–4
 - philosophical position 81
- nootropics 2–3, 44 *see also* enhancement 2–3, 45
- obsessive-compulsive disorder (OCD) 7–8, 70
 - brain-mind mechanisms 86
 - effects of pharmacotherapy 76
 - effects of psychotherapy 76–7
 - explanatory models 84–5
 - placebo effects 78–80
- ‘off-label’ indications for psychotropics 9, 49
- organic model of psychiatric disorder 25–6
- performance enhancement with
 - psychotropics vii–ix, 8
 - military use 5, 8
- personal identity *see* self
- personality, effects of psychotropics
- pharmaceutical, definition 12
- pharmaceutical industry
 - ‘disease mongering’ claims 53–4
 - funding of research on psychotropics 5–6
 - safety regulation 7
- pharmacodynamics 45–6
- pharmacokinetics 45–6
- pharmacological treatment, effects on the self 66–8
- pharmacotherapy
 - classical perspective on effects 72–3
 - classical position on choice of treatment 110–11
 - cognitive-affective science data on treatment choice 113–14
 - concerns about medical technologies 112–13
 - critical perspective on effects 73–4
 - critical position on choice of treatment 111–13
 - ethical questions about use 109–16
 - ethics of use for depression 109–10, 114
 - ethics of use for enhancement 116–30
 - ethics of use for PTSD 114–15
 - evolutionary explanations of effects 86–7
 - integrative view on choice of treatment 113–14
 - justification for use 109–16
 - meanings of different kinds of intervention 111–13
 - see also* psychotropic treatment; psychotropics
 - ‘pharmacotherapeutic dissection’ approach 7–8
- phenomenology 22
- philosophy of emotion 55–6
- philosophy of mind
 - classical approaches 21
 - embodied brain-mind 30–2
- philosophy of psychopharmacology, possibility of a naturalist approach 131–40
- philosophy of self 64–5
- placebo-controlled trials
 - ethics of 81
 - philosophical position 81
- placebo response viii, 13, 78–84
 - and symbolic grounding 81–2
 - and the unconscious 82–4
 - classical view 79
 - clinical implications 84
 - cognitive-affective science perspective 83–4
 - critical view 79–80
 - implications for brain-mind models 81–2
 - OCD 78–80
 - randomised clinical trials 79
 - view of cognitive-affective science 80–1
- placebo Turing Test (PTT) 81–2
- Plato ix, 19–20, 51–2, 53, 59–60, 99

Cambridge University Press

978-0-521-85652-2 - Philosophy of Psychopharmacology: Smart Pills, Happy Pills, and pep Pills

Dan J. Stein

Index

[More information](#)

- positivism 20
- post-traumatic stress disorder (PTSD) 70
 - justification for pharmacotherapy 114–15
- prototypes 27–8, 29, 39, 40
- Prozac 4, 14–15, 87
- psilocybin 45
- psychedelic effects of psychotropics 45
- psychiatric disorder
 - approaches to definition 25–7
 - biopsychosocial model 41
 - classical approach to definition ix, 21–2, 25–6
 - clinical models 25–7
 - conceptual questions viii
 - critical approach to definition ix, 26–7
 - ‘disease mongering’ claims 53–4
 - ethics of psychotropic drug treatment viii
 - evolutionary explanations 87–97
 - global burden 6
 - metaphors of disorder 34–8
 - naturalist approach to categorizing 27–34
 - organic model 25–6
 - underdiagnosis and undertreatment 6–7
 - see also* disorder; medical disorder
- psychiatric drugs, range of potential uses vii–ix
- psychiatry
 - anti-psychiatry movement 6, 62, 66
 - deinstitutionalization of psychiatric patients 6–7
 - influence of psychopharmacology 5
- psychoanalysis 19–20
 - classical view 82–3
 - critical view 83
 - decentred self concept 61
 - interpersonal schools 22
 - philosophy of mind 21
 - placebo response and the unconscious 82–4
- psychological phenomena, critical approach 23–4
- psychology
 - discursive turn 23–4
 - philosophy of mind 21
- psychopathology
 - classical perspective 72–3
 - critical perspective 73–4
 - integrative perspective 77–8
 - mediation of the embodied brain-mind 77–8
 - obsessive-compulsive disorder (OCD) 70
 - origins of 70–8
 - post-traumatic stress disorder (PTSD) 70
- psychopharmacology
 - advent of empirical approach 3–4
 - adverse effects of psychotropics 5
 - benefits from modern developments 6–7
 - complex effects of psychotropics 4–5
 - definition 1
 - deinstitutionalization of psychiatric patients 6–7
 - development and marketing 5–6
 - first generation psychotropics 4
 - gaps in understanding 7, 8–9
 - global burden of psychiatric disorders 6
 - history of 3–4
 - history of human use of psychotropics 1–2
 - impact of new agents on diagnostic constructs 38–9
 - influence on psychiatry 5
 - lack of clinical research data 8–9
 - lack of innovative new agents 7
 - modes of action of agents 3
 - ‘off-label’ indications for psychotropics 9
 - ‘pharmacotherapeutic dissection’ approach 7–8
 - psychotropic targets in the nervous system 3
 - range of psychotropics available 3
 - range of uses for psychotropics 2–3

Cambridge University Press

978-0-521-85652-2 - Philosophy of Psychopharmacology: Smart Pills, Happy Pills, and pep Pills

Dan J. Stein

Index

[More information](#)**208 Index**

- psychopharmacology (*cont.*)
 - relationship with the pharmaceutical industry 5–6
 - research funding issues 5–6
 - safety of modern psychotropics 7
 - second generation psychotropics 4–5
 - side effects of psychotropics 5
 - socio-political issues 5–6
 - sources of psychotropics 3
 - understanding of mechanisms of action 7
- psychotherapy 23–4
 - classical perspective on effects 72–3
 - critical perspective on effects 73–4
 - data from cognitive-affective science 74–6
 - effects on the self 61–2
 - influence of psychopharmacology 5
 - integrative perspective on effects 77–8
 - underlying mechanisms 74–6
 - understanding how it works 13
- psychotropic actions
 - evolutionary perspective 13–14
 - explanatory questions 13–14
 - nocebo effects 13
 - placebo effects 13
 - understanding how treatment works 13
- psychotropic definition 12
 - boundaries with legal and illegal drugs 12
 - categories used to define disorders 12
 - conceptual questions 11–12
 - definition of character and the self 12
 - definition of medical or psychiatric disorder 12
 - distinction between mechanisms of action 12
 - distinction between therapy and enhancement 12
- psychotropic treatment
 - adverse effects 5
 - appropriate symptoms for treatment 14
 - complex effects 4–5
 - cosmetic psychopharmacology 14–15
 - cross-species effects 86–7
 - data from cognitive-affective science 74–6
 - descriptions of mood-enhancement 45
 - difficulty of predicting response 127–9
 - distinction between treatment and enhancement 44–50
 - downstream effects 7
 - effects at 2nd and 3rd messenger level 7
 - effects on the self 61–5
 - ethics of pharmacotherapeutic intervention 109–16
 - ethics of treatment of psychiatric disorders 100–9
 - ethics of use for enhancement 116–30
 - explanatory questions viii
 - integrative perspective on effects 77–8
 - mediation of the embodied brain-mind 77–8
 - moral questions viii, 14–15
 - performance enhancement in the military 5
 - side effects 5
 - use for enhancement/self-improvement 14–15
 - use for performance enhancement 8
 - see also* pharmacotherapy
- psychotropics
 - ‘chemical straitjackets’ criticism 6
 - development and marketing 5–6
 - discovery of 4
 - distinctions between types and uses 44–50
 - first generation 4
 - history of use by humans 1–2
 - influence on psychiatry 5
 - lack of clinical research data 8–9
 - lack of innovative new agents 7
 - marketing as panaceas 6
 - modes of action 3
 - neuromodulatory effects 4–5
 - range available 3
 - range of uses for 2–3
 - safety regulation 7

Cambridge University Press

978-0-521-85652-2 - Philosophy of Psychopharmacology: Smart Pills, Happy Pills, and pep Pills

Dan J. Stein

Index

[More information](#)

- second generation 4–5
- size of the market 5
- socio-political issues 5–6
- sources of 3
- study of 1
- targets in the nervous system 3
- underlying mechanisms 74–6
- understanding of mechanisms of action 7
- see also* pharmacotherapy
- randomized clinical trials
 - classical view 79
 - critical view 79–80
 - ethics of using placebo control 81
 - placebo control 79
- regulation of the pharmaceutical industry 7
- religious or mystic uses of psychotropics 45
- research on psychotropics
 - funding issues 5–6
 - lack of innovative new psychotropics 7
- Roschian categories 28–9
- Russell, Bertrand 20
- schizophrenia 8, 66
- scientific method 20
- selective serotonin reuptake inhibitors (SSRIs) 4–5, 46, 47–8, 87
 - use for enhancement vs treatment 128
- self
 - anthropological data 63–4
 - artificial intelligence approach 63
 - classical approach to definition 59–61
 - critical approach to definition 61–2
 - data from cognitive-affective science 62–5
 - data from cognitive psychology 63
 - decentred self concept 61
 - definition of 12
 - developmental data 64–5
 - effects of pharmacological treatment 66–8
 - effects of psychotherapy 61–2
 - effects of psychotropics 61–5
 - embodiment in the brain-mind 62–5
 - evolutionary data 64–5
 - idea of the individual 61–2
 - linguistic data 63–4
 - nature of 59–68
 - neuroscience data 64
 - persons as nations or clubs 65–6
 - role of narrative 63–4
 - self-deception 67–8
 - self-illness ambiguity 66
 - true self (Essential Self) 63–4, 65, 66–7
 - view of philosophy 65–6
- self-deception 67–8
- self-illness ambiguity 66
- self-representation 59–68
- self-schemas 63, 67–8
- serotonin system, effects of psychotropics 4–5
- side effects of psychotropics 5
- situated cognitivism 22, 24, 77–8
- smart drugs vii–ix
- social anxiety (disorder) 44, 46, 50, 51, 89–90, 96
 - classical perspective 52
 - critical view 53–4
 - DSM classification 58
 - effects of treatment on the self 66–8
 - ethics of decision to treat 106–8
 - integrative approach 57–9
 - research data 57–9
- social deviance, use of psychotropics to control 6
- socio-political issues in psychopharmacology 5–6
- Socrates 67–8
- spandrels 94–5
- Spinoza, Baruch de 32
- spiritual or mystic uses of psychotropics 45
- SSRIs (selective serotonin reuptake inhibitors) 4–5, 46, 47–8, 87
 - use for enhancement vs treatment 128
- St. John's Wort 48
- symbolic cognitivism 19–20, 21, 51–2, 77–8

Cambridge University Press

978-0-521-85652-2 - Philosophy of Psychopharmacology: Smart Pills, Happy Pills, and pep Pills

Dan J. Stein

Index

[More information](#)**210 Index**

- symbolic grounding, implications of
 - placebo and nocebo responses 81–2
- therapeutic options
 - classical position on choice of treatment 110–11
 - critical position on choice of treatment 111–13
 - data from cognitive-affective science 113–14
 - meanings of different kinds of
 - intervention 111–13
- therapy, distinction from enhancement 12
- thymoleptic properties of psychotropics 45
- Total Turing Test (TTT) 81–2
- transference 23–4
- treatment of psychiatric disorders
 - bioethical principlism 103–4
 - care ethics 104
 - classical ethical perspective 101,102–3
 - critical ethical perspective 101–2,103–4
 - data from cognitive-affective science 104–6
 - ethical questions 100–9
 - ethics of cognitive therapy 101,102
 - ethics of depression treatment 100–6
 - ethics of medical decision-making 104–6
 - ethics of social anxiety disorder
 - treatment 106–8
 - ethics of treatment of impulsivity 108–9
 - integrative ethical approach 104–6
 - medicalization of distress 103–4
- unconscious
 - and placebo response 82–4
 - classical view 82–3
 - cognitive-affective science perspective 83–4
 - cognitive scientific view 82
 - critical view 83
 - implicit and explicit processes 82
- Vico, Giambattista ix,22–3
- Wittgenstein, Ludwig ix, x,19–20,23,27, 32,82–3